CN104707101B - A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes - Google Patents
A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes Download PDFInfo
- Publication number
- CN104707101B CN104707101B CN201510088489.7A CN201510088489A CN104707101B CN 104707101 B CN104707101 B CN 104707101B CN 201510088489 A CN201510088489 A CN 201510088489A CN 104707101 B CN104707101 B CN 104707101B
- Authority
- CN
- China
- Prior art keywords
- composition
- extract
- liver cancer
- cancer
- turmeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer, it is 1~10 that said composition, which includes mass ratio,:1:1~10 bupleurum extract, Turmeric P.E and anemarrhena asphodefoides extract.Experiment in vitro proves that composition of the present invention can significantly inhibit lung cancer cell line and hepatoma cell strain growth, IC50Up to 20mg/mL (crude drug amount) below, experiment in vivo proves that said composition can inhibit liver cancer and Growth of Osteosarcoma, improves immune function index, extends ehrlich ascites tumor (EAC) the animal survival phase, and toxic side effect is relatively low.Chinese medicine composition compatibility of the present invention is reasonable, and drug effect is notable, and three is indispensable.Therefore, Chinese medicine composition anti-liver cancer and anti-lung cancer effects of the present invention have potentiality to be exploited.
Description
Technical field
The present invention relates to a kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer, belong to technical field of traditional Chinese medicines.
Background technology
WHO Report claims, and cancer, which has surmounted heart disease, becomes the number one killer for endangering human life and health.
In recent years, in the world, increase cases of cancer newly and cancer death is led with annual 1% speed increase, and China, Russia
The speed that Ross and these countries of India increase is faster.Therefore prevention and treatment cancer, is a disaster of 21 century facing mankind
Topic.The exploitation of antitumor drug becomes the important topic of pharmaceutical researchers in recent years with developing.The chemotherapeutic for the treatment of cancer exists
Toxic side effect is big, the deficiency of somewhat expensive, and the choice drug of many treatment tumours derives from plant at present, such as taxol, camplotheca acuminata
Alkali, vincristine etc..Chinese medicine treatment disease emphasizes dialectical treatmert and wholistic therapy, multicomponent Mutiple Targets treating cancer, so from
Theory of traditional Chinese medical science is set out, and the unique antitumor drug of effect and antitumour auxiliary drug are filtered out in Chinese herbal medicine becomes current domestic
The hot spot of Chinese medicine study.
Radix bupleuri first recorded in《Sheng Nong's herbal classic》, top grade is classified as, for traditional conventional Chinese medicine, applicating history is long, medicinal part
For root, there is evacuation to bring down a fever, is soothing the liver, rising Yang and other effects.Cure mainly the diseases such as flu, fever, fevers and chills alternate, fullness and discomfort in chest and hypochondrium.Radix bupleuri contains
Have a variety of chemical compositions, reported so far containing saponin(e, lignanoid, flavones, volatile oil, cumarin, sterol, organic acid,
The component such as polysaccharide and polyacetylene.Modern pharmacology experiment proves that radix bupleuri has antipyretic, anti-inflammatory, calmness, liver protection, reduces blood pressure, slows down the heart
The multiple biological activities such as rate.Saikoside has anti-inflammatory, anti-experimental character hepatic injury, antitumor, adjusting endocrine and immune system
Function.Saikosaponin a, b, c, d were isolated from Bupleurum falcatum at first in 1966 in Kubo field etc..The report radix bupleuri such as Song Jinggui carries
Take thing to human hepatocarcinoma BEL-7402 Metabolism of Mitochondria activity, cell Proliferation and mouse transplanting S180 entity tumors have it is bright
Aobvious inhibitory action.The report saikosaponin a such as Wang Yanli can extend the syngignoscism of cyclobarbital, it was demonstrated that saikoside can
It can be suppressed liver drug metabolism enzyme system, prevent metabolism of the cancer therapy drug with killing cytosis in liver, make
Obtain drugs against tumor effect enhancing.The report Xiao Chaihu Tang such as Yang Huiling has obvious inhibiting effect, inhibitory rate to mice with tumor S180
40.19%~58.73%.The report Xiao Chaihu Tang water such as Li Jiang puies forward group, graded ethanol group and alcohol water group to H22 rat liver cancer entities
Knurl has obvious inhibiting effect, tumour inhibiting rate difference 32.35%, 43.97% and 25.77%.Disclosed in Chinese patent CN1706454
A kind of anticancer pharmaceutical composition to act synergistically with radix bupleuri and polymycin.
Turmeric first recorded in《Tang materia medica》, the dry rhizome for being zingiberaceous plant turmeric Curcuma longa L., its nature and flavor is pungent,
Bitter, temperature, returns spleen, Liver Channel, have the effect of blood-breaking, inducing meastruation to relieve menalgia, available for chest side of body shouting pain, chest impediment and cardialgia, and dysmenorrhoea Amenorrhea,
The treatment of the illnesss such as Disorder lumps in the abdomen, rheumatism shoulder arm pain, tumbling and swelling.Turmeric contains a variety of chemical compositions, and main component is curcumin
Class compound：Curcumin, Bisdemethoxycurcumin, Demethoxycurcumin, dihydro curcumin etc.；Sesquiterpenoids：
The new ketone of turmeric, turmeric keto-alcohol A, B etc.；Volatile oil (4.2%)：Turmerone, curcumene, rcumenol etc..The active ingredients such as curcumin
Pharmacological action it is extensive, the effect such as its anti-inflammatory, anti-oxidant, antiatherosclerosis, antidepression, antitumor has been commonly recognized,
After wherein antitumor action proposed first from 1985, existing substantial amounts of experimental study confirms that mechanism of action mainly includes induction
Apoptosis of tumor cells, suppresses angiogenesis, arresting cell cycle progression and reversing multiple medicine resistance of tumor cells etc..Huang Dongsheng etc. is ground
Study carefully discovery, curcumin can strengthen the expression of Caspase-8, so as to start exogenous apoptosis pathway, induction human lung carcinoma cell withers
Die.Side is happy to wait report curcumin to have the function that the digestive system tumors such as anti-cancer of the esophagus, stomach cancer, liver cancer, colon cancer.Chinese patent
CN1931353A discloses curcumin extraction and its pharmaceutical composition preparation method.
Rhizoma anemarrhenae comes from《Sheng Nong's herbal classic》, be monocotyledon Liliaceae rhizoma anemarrhenae dry rhizome, be famous Chinese medicine.Its property
Bitter, sweet, cold, return lung, stomach, kidney channel, there is nourishing yin and lessening fire, moisturize laxation, the effect of sharp stool and urine.Available for fever caused by exogenous pathogenic factors, high fever is tired of
Yearningly, the diseases such as lung-heat type cough, osteopyrexia and fever, Heat Diabetes, dry constipation of intestines.Through modern Natural Medicine Chemistry and pharmaceutical research table
Bright, containing steroid saponin, flavones, lignanoid, polysaccharide, sterol and fat oil etc. in rhizoma anemarrhenae, wherein saponin(e is its main component.With
It is past and anti-aging (asphonin), antidepression (anemarrhena total saponin) are all concentrated on substantially to the pharmacology activity research of rhizoma anemarrhenae at present, controlled
Treat Alzheimer disease (timosaponin Q), the field such as anti-type-II diabetes (mangiferin), play be substantially protection cell or
Promote the effect of cell Proliferation, but the research in anti-tumor aspect is seldom.Wang Lijuan etc. has found the Dioscin in rhizoma anemarrhenae
Member has significant inhibitory action in Mice Body to sarcoma, ascitic type liver cancer and cervical carcinoma etc., in vitro to mouse lung epithelioma
Cell, human cervical carcinoma cell and human breast cancer cell etc. also have obvious inhibitory action.Sy etc. has found that Anemarrhena saponin AIII has and lures
Send out Hela apoptosis of tumor cells effect, and find Anemarrhena saponin AIII sugar chain be activity key structure, its parent nucleus chinaroot greenbrier
Sapogenin is without corresponding activity.Timosaponin in rhizoma anemarrhenae is disclosed in Chinese patent CN103599122A and is preparing antineoplastic
The application of thing.
Radix bupleuri is antipyretic and antidotal type medicine, and saikosaponin a and saikoside d contained therein, have obvious antitumor action,
The tumour growth that the bupleurum extract can inhibit tumor-bearing mice is used alone, but the weight of animals increase can be caused to slow down, presents
Certain toxic side effect, after compatibility turmeric and anemarrhena asphodefoides extract, the weight of animals increase recovers normal, and tumor control rate significantly improves.
Chinese prescription compatibility needs the support of theory of traditional Chinese medical science and the verification of therapeutic effect, and composition radix bupleuri of the present invention is pungent, bitter, micro-
Cold, rhizoma anemarrhenae is bitter, sweet, cold, turmeric acrid, bitter, warm, and four gas are gentle after three's compatibility, and the five tastes belong to bitter, and hardship can restrain, swollen beneficial to slowing down
Knurl is grown.Anti-liver cancer and anti-lung cancer effect is with the obvious advantage after experimental result confirms three's compatibility, non-any three tastes Chinese herbal medicine for preventing combination
Institute is attainable.
The content of the invention
The purpose of the present invention is overcome the deficiencies of the prior art and provide a kind of anti-liver cancer and anti-high to liver cancer and lung cancer inhibiting rate
With the Chinese medicine composition of lung cancer.
Second object of the present invention is to provide a kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and is preparing anti-liver cancer and anti-and lung
The purposes of the medicine of cancer.
Technical scheme is summarized as follows：
A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer, including mass ratio are 1~10:1:1~10 bupleurum extract, ginger
Yellow extract and anemarrhena asphodefoides extract.
The mass ratio of bupleurum extract, Turmeric P.E and anemarrhena asphodefoides extract is preferably 5:1:5.
Above-mentioned composition can also include pharmaceutically acceptable auxiliary material.
A kind of above-mentioned Traditional Chinese medicinal composition for treating lung cancer and liver cancer is preparing the purposes of anti-liver cancer and anti-lung cancer medicine.
Preferably, bupleurum extract is extracted with following methods：Radix bupleuri be crushed into 40~50 mesh sieves, with 6~10 mass times
Concentration for 75%~85% ethanol water immersion 1~2 it is small when, heating and refluxing extraction 2~3 times, every time 1~2 it is small when, filtering,
Merge extracting solution, when standing 18~24 is small, 4000~8000rpm is centrifuged 3~10 minutes, takes supernatant, is concentrated, and is freeze-dried, and is done
Dry thing crushes, and 100~200 mesh sieves is crossed, up to bupleurum extract.
Preferably, Turmeric P.E is extracted with following methods：Turmeric is crushed, with the distilled water immersion 1 of 6~10 mass times
~2 it is small when, heating and refluxing extraction 2~3 times, every time 2~3 it is small when, filtering, merge extracting solution, stand 18~24 it is small when, 4000~
8000rpm is centrifuged 3~10 minutes, takes supernatant, is concentrated, dry, and dried object crushes, and crosses 100~200 mesh sieves, is extracted up to turmeric
Thing.
Preferably, anemarrhena asphodefoides extract is extracted with following methods：Rhizoma anemarrhenae is small with the distilled water immersion 1~2 of 5~10 mass times
When, heating and refluxing extraction 2~3 times, every time 2~3 it is small when, filtering, merge extracting solution, stand 18~24 it is small when, 4000~
8000rpm is centrifuged 3~10 minutes, takes supernatant, is concentrated, and freeze-drying, dried object crushes, and 100~200 mesh sieves is crossed, up to rhizoma anemarrhenae
Extract.
Advantages of the present invention：
Prove that the composition of the present invention has through mtt assay experiment in vitro and suppress A549 lung cancer cell lines, LA795 lung carcinoma cells
Strain and BEL-7402 hepatoma cell strains, HepG2 hepatoma cell strain growths, IC50Up to 20mg/mL (crude drug amount) below；Animal
Experiment in vivo proof can inhibit H22 liver cancer and S180 Growth of Osteosarcoma, and inhibiting rate is respectively 55 ± 2.36%, 53 ± 4.62%.
Immune function of mice index (spleen index, thymus index) dramatically increases.The life of ehrlich ascites tumor (EAC) mouse middle position can also be extended
Deposit the phase, the median survival interval of mouse extended to 17.15 ± 0.23 days by 12.91 ± 0.86 days.Illustrate toxic side effect reduction.This hair
The each component of bright composition has synergistic function, not only can inhibit tumour growth, can also extend the ascites tumor life of animal
The phase is deposited, quality of making the life better.Chinese medicine composition prescription compatibility of the present invention is reasonable, by pungent, warm turmeric and radix bupleuri and rhizoma anemarrhenae
Cold and cool property.Polysaccharide component contained by turmeric and rhizoma anemarrhenae, which has effects that to improve, to be immunized, and on the one hand improves antitumor action, another
Aspect reduces toxic side effect, improves immunity.Therefore, three's compatibility can play good antitumor action.
Embodiment
With reference to specific embodiment, the present invention is further illustrated.
1~embodiment of embodiment 9 discloses the extracting method of bupleurum extract, Turmeric P.E and anemarrhena asphodefoides extract, institute
It is noted that the extracting method of these extracts be disclosed to those skilled in the art is better understood when this hair
It is bright, but the present invention is not imposed any restrictions, the extract that other methods obtain, its active ingredient is carried with disclosed by the invention
Take thing active ingredient it is similar can be used for the present invention.
Embodiment 1
Bupleurum extract is extracted with following methods：Radix Bupleuri be crushed into 40 mesh sieves, the concentration with 10 mass times is
75% ethanol water immersion 1 it is small when, heating and refluxing extraction 2 times, every time 1 it is small when, filtering, merge extracting solution, stand 18 it is small when,
4000rpm is centrifuged 10 minutes, takes supernatant, is concentrated, and freeze-drying, dried object crushes, and 200 mesh sieves is crossed, up to bupleurum extract.
Embodiment 2
Bupleurum extract is extracted with following methods：Radix Bupleuri be crushed into 40 mesh sieves, be 85% with the concentration of 6 mass times
Ethanol water immersion 1.5 it is small when, heating and refluxing extraction 3 times, every time 1.5 it is small when, filtering, merge extracting solution, stand 24 it is small when,
8000rpm is centrifuged 3 minutes, takes supernatant, is concentrated, and freeze-drying, dried object crushes, and 100 mesh sieves is crossed, up to bupleurum extract.
Embodiment 3
Bupleurum extract is extracted with following methods：Radix Bupleuri be crushed into 50 mesh sieves, be 80% with the concentration of 8 mass times
Ethanol water immersion 2 it is small when, heating and refluxing extraction 2 times, every time 2 it is small when, filtering, merge extracting solution, stand 20 it is small when,
6000rpm is centrifuged 7 minutes, takes supernatant, is concentrated, and freeze-drying, dried object crushes, and 100 mesh sieves is crossed, up to bupleurum extract.
Embodiment 4
Turmeric P.E is extracted with following methods：Turmeric is crushed, when small with the distilled water immersion 1.5 of 8 mass times, heating
Refluxing extraction 3 times, every time 3 it is small when, filtering, merge extracting solution, stand 20 it is small when, 6000rpm centrifuge 7 minutes, take supernatant, it is dense
Contracting, dry, dried object crushes, and 100 mesh sieves is crossed, up to Turmeric P.E.
Embodiment 5
Turmeric P.E is extracted with following methods：Turmeric is crushed, when small with the distilled water immersion 1 of 10 mass times, heating
Refluxing extraction 3 times, every time 2 it is small when, filtering, merge extracting solution, stand 18 it is small when, 4000rpm centrifuge 10 minutes, take supernatant, it is dense
Contracting, dry, dried object crushes, and 100 sieves is crossed, up to Turmeric P.E.
Embodiment 6
Turmeric P.E is extracted with following methods：Turmeric is crushed, when small with the distilled water immersion 2 of 6 mass times, is heated back
Stream extraction 2 times, every time 3 it is small when, filtering, merge extracting solution, stand 24 it is small when, 8000rpm centrifuge 3 minutes, take supernatant, concentrate,
Dry, dried object crushes, and 200 sieves is crossed, up to Turmeric P.E.
Embodiment 7
Anemarrhena asphodefoides extract is extracted with following methods：By rhizoma anemarrhenae it is small with the distilled water immersion 2 of 5 mass times when, be heated to reflux carrying
Take 3 times, every time 2 it is small when, filtering, merges extracting solution, stand 24 it is small when, 8000rpm is centrifuged 3 minutes, takes supernatant, is concentrated, freezing
Dry, dried object crushes, and 100 mesh sieves is crossed, up to anemarrhena asphodefoides extract.
Embodiment 8
Anemarrhena asphodefoides extract is extracted with following methods：By rhizoma anemarrhenae it is small with the distilled water immersion 1.5 of 8 mass times when, be heated to reflux
Extraction 2 times, every time 3 it is small when, filtering, merge extracting solution, stand 22 it is small when, 6000rpm centrifuge 7 minutes, take supernatant, concentrate, it is cold
Lyophilized dry, dried object crushes, and 100 mesh sieves is crossed, up to anemarrhena asphodefoides extract.
Embodiment 9
Anemarrhena asphodefoides extract is extracted with following methods：By rhizoma anemarrhenae it is small with the distilled water immersion 1 of 10 mass times when, be heated to reflux carrying
Take 2 times, every time 2 it is small when, filtering, merges extracting solution, stand 18 it is small when, 4000rpm is centrifuged 10 minutes, takes supernatant, is concentrated, freezing
Dry, dried object crushes, and 200 mesh sieves is crossed, up to anemarrhena asphodefoides extract.
Embodiment 10
A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer, including mass ratio are 5:1:5 bupleurum extract (make by embodiment 3
It is standby), Turmeric P.E (prepared by embodiment 4) and anemarrhena asphodefoides extract (prepared by embodiment 8).
Embodiment 11
A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer, including mass ratio are 10:1:1 bupleurum extract (make by embodiment 2
It is standby), Turmeric P.E (prepared by embodiment 6) and anemarrhena asphodefoides extract (prepared by embodiment 7).
Embodiment 12
A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer, including mass ratio are 1:1:10 bupleurum extract (make by embodiment 1
It is standby), Turmeric P.E (prepared by embodiment 5) and anemarrhena asphodefoides extract (prepared by embodiment 9).
Embodiment 13
A kind of test of pesticide effectiveness of Traditional Chinese medicinal composition for treating lung cancer and liver cancer of the present invention：
One, anti-tumor activity test methods
1. anti tumor activity in vitro is tested
BEL-7402 hepatoma cell strains, are incubated at containing 10% inactivated fetal bovine serum, 100U/mL penicillin and 100 μ g/mL chains
In the RPMI-1640 culture mediums of mycin, in 37 DEG C, 5%CO2Cultivated under the conditions of incubator and saturated humidity, passage one in 3~4 days
It is secondary.
HepG2 hepatoma cell strains, are incubated at containing 10% inactivated fetal bovine serum, 100U/mL penicillin and 100 μ g/mL strepto-s
In the DMEM culture mediums of element, in 37 DEG C, 5%CO2Cultivated under the conditions of incubator and saturated humidity, passage in 3~4 days is once.
Human pulmonary epithelial cells strain, is incubated at containing 10% inactivated fetal bovine serum, 100U/mL penicillin and 100 μ g/mL chains
In the DMEM culture mediums of mycin, in 37 DEG C, 5%CO2Cultivated under the conditions of incubator and saturated humidity, passage in 3~4 days is once.
Mouse pulmonary adenocarcinoma cell line LA 795 strain, is incubated at containing 10% inactivated fetal bovine serum, 100U/mL penicillin and 100 μ g/
In the RPMI-1640 culture mediums of mL streptomysins, in 37 DEG C, 5%CO2Cultivate, pass under the conditions of incubator and saturated humidity within 3~4 days
In generation, is once.
Mtt assay：Concentration is configured to after exponential phase cell is digested with pancreatin as 3 × 104The cell suspension of a/mL,
96 hole elisa Plates are inoculated in, add 200 μ L per hole.Not serum-containing medium is changed after 24h grows cell synchronization, per 200 μ L of hole.
By reagent is added into hole within 3rd day, that is, be separately added into bupleurum extract (prepared by embodiment 3) aqueous solution, Turmeric P.E is (real
Example 4 is applied to prepare) aqueous solution and anemarrhena asphodefoides extract (prepared by embodiment 8) aqueous solution, embodiment 10, embodiment 11, embodiment 12 are made
Standby composition solution；Separately set control group：0.1% dimethyl sulfoxide (DMSO) (DMSO), adds 200 μ L per hole.Every group of difference of by reagent
If 0.01,0.1,1,10,100,1000 concentration of μ g/mL six, each concentration set 8 parallel holes, after cultivating 24h at 37 DEG C,
Add 0.5mg/mL MTT 100 μ L of the serum-free without phenol red nutrient solution Fresh per hole, continue to cultivate 4h, then, add per hole
100 μ L DMSO dissolve MTT formazan particles, and after being mixed with microoscillator vibration, OD value (OD) is measured in microplate reader,
Experiment in triplicate, is averaged.Tumour cell is handled as control group using solvent control, inhibiting rate is calculated by OD values, formula is：
Inhibitory rate of cell growth=(control group OD values-experimental group OD values)/control group OD × 100%, and using drug concentration as horizontal seat
Mark, OD values are ordinate, draw cell growth curve, and try to achieve IC50(half inhibiting rate), IC50(crude drug amount)=cell growth
Inhibiting rate is 50% drug concentration.It the results are shown in Table 1.
1 anti tumor activity in vitro result of the test of table
2. anti-tumor activity test in body
2.1H22Liver cancer model is tested
2.1.1 animal model
Mouse H is carried out to the composition of the present invention with 140 kunming mices (female, 18~20g)22Medicine in liver cancer model body
Effect experiment.
Take inoculation H22Liver cancer cells well-grown tumor-bearing mice of ascites after 6~8 days, sterilizes belly, in superclean bench
Middle extraction milky ascites is knurl source, takes ascites 10mL, is 1 in proportion by ascites and physiological saline:1 mixing, is made into cell and hangs
Liquid, extracts 0.1mL with asepsis injector, is inoculated under every kunming mice right fore armpit.Whole operation is aseptically
Carry out.2.1.2 animal packet and administration
H will be inoculated with22140 kunming mices of liver cancer cells are divided into 14 groups, every group 10.Inoculation next day starts to be administered, often
Day 1 time：(1) model group, gavages physiological saline, every 0.2mL；(2) chemotherapy group：Ring phosphinylidyne is injected intraperitoneally by 20mg/kgbw
Amine；(3) bupleurum extract (prepared by embodiment 3) high dose group：Bupleurum extract 0.2mL is gavaged by 6g (crude drug amount)/kgbw；
(4) bupleurum extract (prepared by embodiment 3) low dose group：Bupleurum extract 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(5)
Turmeric P.E (prepared by embodiment 4) high dose group：Turmeric P.E 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(6) ginger
Yellow extract (prepared by embodiment 4) low dose group：Turmeric P.E 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(7) rhizoma anemarrhenae
Extract (prepared by embodiment 8) high dose group：Anemarrhena asphodefoides extract 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(8) rhizoma anemarrhenae carries
Take thing (prepared by embodiment 8) low dose group：Anemarrhena asphodefoides extract 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(9) embodiment 10
High dose group：Composition 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(10) 10 low dose group of embodiment：By 3g (crude drugs
Amount)/kgbw gavages composition 0.2mL；(11) 11 high dose group of embodiment：Composition is gavaged by 6g (crude drug amount)/kgbw
0.2mL；(12) 11 low dose group of embodiment：Composition 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(13) embodiment 12 is high
Dosage group：Composition 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(14) 12 low dose group of embodiment：By 3g (crude drug amount)/
Kgbw gavages composition 0.2mL；Two weeks, next day cervical dislocation puts to death mouse after administration, and solution takes its knurl group
Knit, win spleen, thymus gland is simultaneously weighed.Survey tumour inhibiting rate：(i) tumour inhibiting rate (%)=(the 1- administration groups knurl weight/model group that is averaged is averaged knurl
Weight) × 100%, spleen, thymus gland are won, and weigh.Spleen index=(spleen weight/weight) * 1000, thymus index=(chest gland weight
Amount/weight) * 1000, it the results are shown in Table 2 and table 3.
2 H of table22Liver cancer tumor-bearing mice tumour inhibiting rate experimental result
3 H of table22Liver cancer tumor-bearing mice Immune Organs Index
Note：Compared with model group, * P<0.05, * * P<0.01
2.2S180 osteosarcoma model experiments
2.2.1 animal model
Mouse S180 osteosarcoma models are carried out to the composition of the present invention with 140 kunming mices (female, 18~20g)
The interior test of pesticide effectiveness.
Inoculation S180 osteosarcoma cells well-grown tumor-bearing mice of ascites after 6~8 days is taken, belly is sterilized, in ultra-clean work
It is knurl source to make to extract milky ascites in platform, takes ascites 10mL, is 1 in proportion by ascites and physiological saline:1 mixing, is made into thin
Born of the same parents' suspension, extracts 0.1mL with asepsis injector, is inoculated under every kunming mice right fore armpit.Whole operation is in sterile bar
Carried out under part.
2.2.2 animal packet and administration
140 kunming mices for being inoculated with S180 osteosarcoma cells are divided into 14 groups, every group 10.Inoculation next day start to
Medicine, one time a day：(1) model group, gavages physiological saline, every 0.2mL；(2) chemotherapy group：Ring is injected intraperitoneally by 20mg/kgbw
Phosphamide；(3) bupleurum extract (prepared by embodiment 3) high dose group：Bupleurum extract is gavaged by 6g (crude drug amount)/kgbw
0.2mL；(4) bupleurum extract (prepared by embodiment 3) low dose group：Bupleurum extract is gavaged by 3g (crude drug amount)/kgbw
0.2mL；(5) Turmeric P.E (prepared by embodiment 4) high dose group：Turmeric P.E is gavaged by 6g (crude drug amount)/kgbw
0.2mL；(6) Turmeric P.E (prepared by embodiment 4) low dose group：Turmeric P.E is gavaged by 3g (crude drug amount)/kgbw
0.2mL；(7) anemarrhena asphodefoides extract (prepared by embodiment 8) high dose group：Anemarrhena asphodefoides extract is gavaged by 6g (crude drug amount)/kgbw
0.2mL；(8) anemarrhena asphodefoides extract (prepared by embodiment 8) low dose group：Anemarrhena asphodefoides extract is gavaged by 3g (crude drug amount)/kgbw
0.2mL；(9) 10 high dose group of embodiment：Composition 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(10) low dose of embodiment 10
Amount group：Composition 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(11) 11 high dose group of embodiment：By 6g (crude drug amount)/
Kgbw gavages composition 0.2mL；(12) 11 low dose group of embodiment：Composition is gavaged by 3g (crude drug amount)/kgbw
0.2mL；(13) 12 high dose group of embodiment：Composition 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(14) embodiment 12 is low
Dosage group：Composition 0.2mL is gavaged by 3g (crude drug amount)/kgbw；Two weeks, in after administration at next day cervical dislocation
Dead mouse, solution take its tumor tissue, win spleen, and thymus gland is simultaneously weighed.Survey tumour inhibiting rate：(i) tumour inhibiting rate (%)=(1- administration groups are averaged
Knurl weight/model group is averaged knurl weight) × 100%, spleen, thymus gland are won, and weigh.Spleen index=(spleen weight/weight) * 1000,
Thymus index=(thymic weight/weight) * 1000, the results are shown in Table 4 and table 5.
4 S180 osteosarcoma tumor-bearing mice tumour inhibiting rate experimental results of table
5 S180 osteosarcoma tumor-bearing mice Immune Organs Indexes of table
Note：Compared with model group, * P<0.05, * * P<0.01
2.3EAC model test
2.2.1 animal model
Drug effect in mouse EAC models is carried out to the composition of the present invention with 140 kunming mices (female, 18~20g)
Experiment.
Inoculation EAC cells well-grown tumor-bearing mice of ascites after 6~8 days is taken, belly is sterilized, is taken out in superclean bench
It is knurl source to take milky ascites, takes ascites 15mL, is 1 in proportion by ascites and physiological saline:1 mixing, is made into cell suspension.With
Asepsis injector extracts cell suspension, and every mouse peritoneal injects 0.2ml.Whole operation aseptically carries out.
2.2.2 animal packet and administration
140 kunming mices for being inoculated with EAC cells are divided into 14 groups, every group 10.Inoculation next day starts to be administered, and daily 1
It is secondary：(1) model group, gavages physiological saline, every 0.2mL；(2) chemotherapy group：Cis-platinum is injected intraperitoneally by 20mg/kgbw；(3) bavin
Hu extract (prepared by embodiment 3) high dose group：Bupleurum extract 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(4) radix bupleuri
Extract (prepared by embodiment 3) low dose group：Bupleurum extract 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(5) turmeric carries
Take thing (prepared by embodiment 4) high dose group：Turmeric P.E 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(6) turmeric is extracted
Thing (prepared by embodiment 4) low dose group：Turmeric P.E 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(7) anemarrhena asphodefoides extract
(prepared by embodiment 8) high dose group：Anemarrhena asphodefoides extract 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(8) anemarrhena asphodefoides extract is (real
Example 8 is applied to prepare) low dose group：Anemarrhena asphodefoides extract 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(9) 10 high dose of embodiment
Group：Composition 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(10) 10 low dose group of embodiment：By 3g (crude drug amount)/kg
Bw gavages composition 0.2mL；(11) 11 high dose group of embodiment：Composition 0.2mL is gavaged by 6g (crude drug amount)/kgbw；
(12) 11 low dose group of embodiment：Composition 0.2mL is gavaged by 3g (crude drug amount)/kgbw；(13) 12 high dose group of embodiment：
Composition 0.2mL is gavaged by 6g (crude drug amount)/kgbw；(14) 12 low dose group of embodiment：Filled by 3g (crude drug amount)/kgbw
Oral compositions 0.2mL；During the experiment records the death time of every mouse, finally calculates median survival interval and mean survival time (MST).
It the results are shown in Table 6
6 EAC of table extends life cycle experimental result
Note：Compared with model group, * P<0.05, * * P<0.01
Pharmaceutically acceptable auxiliary material is added into the composition of the present invention such as：It is starch, dextrin, Icing Sugar, lactose, rubber cement, poly-
Ethylene glycol, sodium carboxymethylcellulose etc., prepare piece agent, capsule, granule, water-bindered pill agent, pill etc. according to a conventional method.
Data above combines in vitro and in vivo experiments, and experiment in vivo has investigated composition and suppressed implanted solid tumor growth, prolongs again
Long Animals with ascitic tumors life cycle and animal immune shoot formation.Overall merit Chinese medicine composition of the present invention in anti-liver cancer and anti-and
Effect in terms of lung cancer.
Claims (3)
1. a kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer, its feature is 1~10 by mass ratio:1:1~10 bupleurum extract,
Turmeric P.E and anemarrhena asphodefoides extract composition.
A kind of 2. Traditional Chinese medicinal composition for treating lung cancer and liver cancer according to claim 1, it is characterised in that the radix bupleuri extraction
The mass ratio of thing, Turmeric P.E and anemarrhena asphodefoides extract is 5:1:5.
3. a kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer of claim 1 or 2 is preparing anti-liver cancer and anti-as sole active composition
With the purposes of lung-cancer medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510088489.7A CN104707101B (en) | 2015-02-26 | 2015-02-26 | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510088489.7A CN104707101B (en) | 2015-02-26 | 2015-02-26 | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104707101A CN104707101A (en) | 2015-06-17 |
| CN104707101B true CN104707101B (en) | 2018-05-04 |
Family
ID=53407145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510088489.7A Expired - Fee Related CN104707101B (en) | 2015-02-26 | 2015-02-26 | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104707101B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108079249A (en) * | 2017-12-28 | 2018-05-29 | 晨光生物科技集团邯郸有限公司 | A kind of Chinese medicine preparation with liver protection and preparation method thereof |
| CN109432355A (en) * | 2018-11-30 | 2019-03-08 | 佛山科学技术学院 | A kind of Chinese medicine composition of anti-liver cancer and anti-and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049484A (en) * | 2007-05-14 | 2007-10-10 | 郝来勤 | Strong effective Chinese traditional medicine for treating lung cancer and other various cancers |
| CN101773636A (en) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | Antitumor nanometer Chinese medicine and production method thereof |
| CN104043057A (en) * | 2014-06-28 | 2014-09-17 | 王星月 | Traditional Chinese medicinal composition for treating lymph cancer |
-
2015
- 2015-02-26 CN CN201510088489.7A patent/CN104707101B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049484A (en) * | 2007-05-14 | 2007-10-10 | 郝来勤 | Strong effective Chinese traditional medicine for treating lung cancer and other various cancers |
| CN101773636A (en) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | Antitumor nanometer Chinese medicine and production method thereof |
| CN104043057A (en) * | 2014-06-28 | 2014-09-17 | 王星月 | Traditional Chinese medicinal composition for treating lymph cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104707101A (en) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112569307B (en) | Traditional Chinese medicine composition for strengthening body resistance and eliminating tumor as well as preparation method and application thereof | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN102114099B (en) | Traditional Chinese medicine preparation for inhibiting liver cancer and preparation method thereof | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN104707101B (en) | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer and purposes | |
| CN104857435A (en) | Chinese herbal compound composition with antineoplastic activity as well as preparation method and application thereof | |
| CN106668811A (en) | Lycium ruthenicum anticancer lifesaving tablets | |
| CN101564466A (en) | Traditional Chinese medicine effective part composition containing antineoplastic active ingredients as well as preparation method and application thereof | |
| CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN102225089B (en) | Pharmaceutical composition for treating cancers, pharmaceutical preparation as well as applications and production methods thereof | |
| CN101352560B (en) | Medicament for treating tumor | |
| CN103933472B (en) | A kind of Traditional Chinese medicinal composition for treating lung cancer and liver cancer | |
| CN103142934A (en) | Traditional Chinese medicinal composition for treating lung cancer and liver cancer | |
| CN103169844B (en) | Traditional Chinese medicine composition having anti-lung cancer and anti-liver cancer effects | |
| CN100411663C (en) | Anticancer compound Chinese medicine powder and its preparing method | |
| CN104825922A (en) | Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition | |
| CN104825783A (en) | Traditional Chinese medicine composition with anti-tumor activity and preparation method and application of traditional Chinese medicine composition | |
| CN103977112A (en) | Traditional Chinese medicament for treating alcoholic liver | |
| CN105617319A (en) | Preparation method of traditional Chinese medicine composition for treating acute cholecystitis | |
| CN102940773A (en) | Chinese medicinal preparation for inhibiting liver cancer metastasis and preparation method thereof | |
| CN114869987B (en) | Traditional Chinese medicine composition for preventing liver cancer | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN106177391A (en) | A kind of pharmaceutical composition treating cancer and preparation method thereof | |
| CN101607009B (en) | A pharmaceutical composition for treating common cold | |
| CN116440210A (en) | Traditional Chinese medicine composition for treating diabetic foot and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180504 Termination date: 20200226 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |